UNSPSC 51262204: Piperoxan hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KS0DZ1UQNW, chemically known as 1,4-benzodioxan, 2-(1-piperidylmethyl)-, hydrochloride but more generally known as piperoxan hydrochloride, which bears US NIH Compound Identifier 101619. Most nations, for tariff and trade purposes, schedule piperoxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PIPEROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Piperoxan hydrochloride bears US NLM identifiers UMLS ID C2825596 and NCI Concept Code C81370. SMILES: C1CCC2C(C1)OCC(O2)CN3CCCCC3.CL.

UNSPSC 51262204 Piperoxan hydrochloride, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The one relevant recent opportunity—Seminole County, Florida's IFB60459723LAS posted June 30, 2026—sought naloxone and drug deactivation systems rather than piperoxan specifically, suggesting the code may be underutilized or misclassified in state and local procurement systems. The second opportunity, the Texas HHS Commission's RFI HHS0017013 posted April 3, 2026, addresses direct-to-manufacturer prescription program capability rather than procurement of a specific pharmaceutical product and does not align with the piperoxan commodity scope. State and local governments appear to procure pharmaceutical products through broader health and human services frameworks rather than as standalone commodity purchases under this specific UNSPSC designation.

The geographic spread of activity is limited to Florida and Texas based on recent posting dates. Seminole County represents a county-level issuing body pursuing public health support through competitive bidding; the Texas HHS Commission represents a state-level health agency conducting exploratory market intelligence. No recent opportunities demonstrate sustained demand for piperoxan hydrochloride itself under this code, and the limited activity suggests that business development professionals should monitor this code for increased frequency rather than pursue immediate opportunities. The mismatch between the code's pharmaceutical specificity and the actual work being solicited indicates either low demand for piperoxan in state and local procurement or classification inconsistency in how public bodies tag pharmaceutical solicitations.